Business
Cardiol Therapeutics Announces Study Results from Collaborating Research Center Demonstrating Cardioprotective Effects of Cannabidiol in a Model of Heart Failure
Results Demonstrate Cannabidiol Improved Cardiac Function, Reduced its Inflammatory State, and Pr...
About this update from Cardiol Therapeutics Inc. Class A
[{"type":"text","content":"Cardiol Therapeutics Announces Study Results from Collaborating Research Center Demonstrating Cardioprotective Effects of Cannabidiol in a Model of Heart FailureResults Demonstrate Cannabidiol Improved Cardiac Function, Reduced its Inflammatory State, and Prevented the Development of Hypertrophy and Fibrosis in Heart TissueData Presented at The American College of Cardiology's 72nd Annual Scientific Session Together with the World Congress of Cardiology Oakville, Ontario--(Newsfile Corp. - March 7, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (\"Cardiol\" or the \"Company\"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases, announced study results from one of its international collaborating research centers demonstrating that its pharmaceutically manufactured cannabidiol significantly prevents cardiac dysfunction and the development of fibrosis and cardiomyocyte hypertrophy in a pre-clinical model of heart failure and reduces expression of key inflammatory and fibrotic markers. Cannabidiol is the active pharmaceutical ingredient in CardiolRx™, the Company's lead investigational oral drug candidate currently in Phase II clinical trials for recurrent pericarditis and acute myocarditis, and in its novel subcutaneously administered drug formulation intended for use in heart failure and currently in pre-clinical development.The studies were presented by researchers from Instituto Tecnológico y de Estudios Superiores de Monterrey, Mexico (\"TecSalud\") at the American College of Cardiology's 72nd Annual Scientific Session together with World Congress of Cardiology (\"ACC.23/WCC\"). TecSalud is one of the Company's international collaborating research centers working towards the common goal of developing therapies to advance the treatment of heart diseases. Dr. Andrew Hamer, Cardiol Therapeutics' Chief Medical Officer and Head of Research & Development commented, \"The beneficial effects of cannabidiol in a pre-clinical model of heart failure are of great interest and importance in support of our ARCHER trial which is investigating recovery of cardiac function in patients with myocarditis. The data provides further evidence of the anti-inflammatory and anti-fibrotic effects of Card...